Antimicrobial Peptides Market 2026: Global Growth Trends, Clinical Pipeline Analysis, and Comparative Efficacy Against Traditional Antibiotics
Abstract: The global antimicrobial peptides (AMPs) market is projected to reach $8.5 billion by 2026 (CAGR 8.2%), driven by rising antibiotic resistance. Clinical pipeline analysis reveals over 60 candidates in trials, with polymyxins (e.g., Colistin) showing superior efficacy against MDR Gram-negative bacteria but higher nephrotoxicity versus traditional antibiotics. Key brands (e.g., Cubicin, Dalbavancin) demonstrate 90%+ efficacy in skin infections. AMPs offer rapid bactericidal action and low resistance potential but suffer from high production costs and enzymatic instability. Market trends favor synthetic lipopeptides and defensins for wound care and food preservation. Product selection prioritizes purity (>95%), endotoxin levels (<0.5 EU/mg), and GMP-certified facilities. Logistics require lyophilized storage at -20°C.